RxDoctor Payments Data

Robert Bernstein, MD

Critical Care Medicine · Ventura, CANPI 1932205119

Payments from drug & device makers

$631in general payments, 2019–2025

Across 20 payments — averaging $31.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$176
  • Boehringer Ingelheim$156
  • Biotronik Inc.$74
  • GSK$62
  • Insmed, Inc.$44
  • Baxter Healthcare$38
  • plus $81 from 3 others

What the payments were for

  • Food & beverage$61798%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$631 in reported general payments places this provider in the 55th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$142,773
Medicare patients
375
Services billed
1,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter152$108,392
Breo ElliptaFluticasone/Vilanterol46$28,883
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$26,483
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$19,954
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$13,489
Arnuity ElliptaFluticasone Furoate32$9,553
SymbicortBudesonide/Formoterol Fumarate20$9,511
Spiriva HandihalerTiotropium Bromide15$8,226
BreynaBudesonide/Formoterol Fumarate31$3,826
Albuterol Sulfate HfaAlbuterol Sulfate160$3,208
Ventolin HfaAlbuterol Sulfate29$2,135
Wixela InhubFluticasone Propion/Salmeterol11$1,916
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,855
Montelukast Sodium56$415
Prednisone79$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$62$173,310279 claims
Boehringer IngelheimStiolto Respimat$156$13,48920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →